1. Home
  2. ETON vs SCM Comparison

ETON vs SCM Comparison

Compare ETON & SCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETON
  • SCM
  • Stock Information
  • Founded
  • ETON 2017
  • SCM 2012
  • Country
  • ETON United States
  • SCM United States
  • Employees
  • ETON N/A
  • SCM N/A
  • Industry
  • ETON Biotechnology: Pharmaceutical Preparations
  • SCM Finance/Investors Services
  • Sector
  • ETON Health Care
  • SCM Finance
  • Exchange
  • ETON Nasdaq
  • SCM Nasdaq
  • Market Cap
  • ETON 428.5M
  • SCM 384.8M
  • IPO Year
  • ETON 2018
  • SCM 2012
  • Fundamental
  • Price
  • ETON $16.84
  • SCM $13.39
  • Analyst Decision
  • ETON Strong Buy
  • SCM Hold
  • Analyst Count
  • ETON 3
  • SCM 1
  • Target Price
  • ETON $29.67
  • SCM $13.00
  • AVG Volume (30 Days)
  • ETON 440.2K
  • SCM 122.6K
  • Earning Date
  • ETON 05-13-2025
  • SCM 05-12-2025
  • Dividend Yield
  • ETON N/A
  • SCM 11.95%
  • EPS Growth
  • ETON N/A
  • SCM 26.74
  • EPS
  • ETON N/A
  • SCM 1.42
  • Revenue
  • ETON $48,327,000.00
  • SCM $103,691,042.00
  • Revenue This Year
  • ETON $103.21
  • SCM $1.85
  • Revenue Next Year
  • ETON $51.34
  • SCM $2.30
  • P/E Ratio
  • ETON N/A
  • SCM $9.40
  • Revenue Growth
  • ETON 40.88
  • SCM N/A
  • 52 Week Low
  • ETON $3.18
  • SCM $11.19
  • 52 Week High
  • ETON $21.48
  • SCM $15.56
  • Technical
  • Relative Strength Index (RSI)
  • ETON 42.38
  • SCM 53.44
  • Support Level
  • ETON $19.56
  • SCM $12.85
  • Resistance Level
  • ETON $19.35
  • SCM $13.30
  • Average True Range (ATR)
  • ETON 1.07
  • SCM 0.23
  • MACD
  • ETON -0.47
  • SCM -0.01
  • Stochastic Oscillator
  • ETON 6.78
  • SCM 62.79

About ETON Eton Pharmaceuticals Inc.

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

About SCM Stellus Capital Investment Corporation

Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through a first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm is functioned through the United States and it generates revenue in the form of interest income on debt investments and capital gains and distributions.

Share on Social Networks: